- Home
- ANVS vs TIL Comparison
ANVS vs TIL Comparison
Compare ANVS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- TIL
- Stock Information
- Founded
- ANVS 2008
- TIL 2018
- Country
- ANVS United States
- TIL United States
- Employees
- ANVS N/A
- TIL N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- TIL Health Care
- Exchange
- ANVS Nasdaq
- TIL Nasdaq
- Market Cap
- ANVS 48.3M
- TIL 177.1M
- IPO Year
- ANVS 2020
- TIL 2021
- Fundamental
- Price
- ANVS $2.32
- TIL $21.55
- Analyst Decision
- ANVS Strong Buy
- TIL Buy
- Analyst Count
- ANVS 4
- TIL 6
- Target Price
- ANVS $17.33
- TIL $120.50
- AVG Volume (30 Days)
- ANVS 198.0K
- TIL 145.1K
- Earning Date
- ANVS 11-07-2025
- TIL 11-12-2025
- Dividend Yield
- ANVS N/A
- TIL N/A
- EPS Growth
- ANVS N/A
- TIL N/A
- EPS
- ANVS N/A
- TIL N/A
- Revenue
- ANVS N/A
- TIL N/A
- Revenue This Year
- ANVS N/A
- TIL N/A
- Revenue Next Year
- ANVS N/A
- TIL N/A
- P/E Ratio
- ANVS N/A
- TIL N/A
- Revenue Growth
- ANVS N/A
- TIL N/A
- 52 Week Low
- ANVS $1.11
- TIL $10.80
- 52 Week High
- ANVS $10.54
- TIL $73.69
- Technical
- Relative Strength Index (RSI)
- ANVS 43.70
- TIL 38.52
- Support Level
- ANVS $2.26
- TIL $22.67
- Resistance Level
- ANVS $2.51
- TIL $25.89
- Average True Range (ATR)
- ANVS 0.11
- TIL 2.61
- MACD
- ANVS 0.01
- TIL -0.62
- Stochastic Oscillator
- ANVS 35.48
- TIL 10.46
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.